Broad ChemoCentryx Inflammation Alliance Plants CEEDD Downstream
This article was originally published in Start Up
Executive Summary
ChemoCentryx's broad deal with GSK's Center for Excellence in External Drug Discovery (CEEDD) moves CEEDD downstream into early clinical territory and sets the biotech up for a potential IPO. The deal also illustrates the difficulties in defining alliance parameters like proof-of-concept.
You may also be interested in...
GSK's Risk-Sharing Deals to Compete with In-House R&D
Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.
Theravance: Having Cake and Eating It
Thanks to productivity, lower-risk follow-on drugs and access to a Big Pharma balance sheet, Theravance is trying to demonstrate the possibility of getting paid for doing what biotech does best: research.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.